Oh yes
I am 80% sure, looking at IOMAB b results, that the FDA would accept change of the SAP plan, given the new orientations of FDA, you are citing OMER, and I have in mind as well NWBO and few others that might make it as well.
The only thing is I am not sure of the timing, so this Ph III might be delayed. Is it better to wait till completion with 100% of data or ask for early termination ? I am not sure what the company prefers, looks like the first option which makes me think they would prefer a normal completion to a lengthy talk. Company is not clear enough. I do not like lack of clarity and we know time is money while cash is burnt.